SCHEMBL965985

SCHEMBL965985

C[C@@H](C(N)=O)c1ccc(NS(=O)(=O)c2c(Cl)cccc2Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.60
GAA P10253 3/20 0.54
PGR P06401 1/20 0.46
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
CXCL8 P10145 1/20 0.42
IDH1 O75874 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.40
PKM P14618 2/20 0.40
IDH2 P48735 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
EPHX1 P07099 1/20 0.40
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31701338 0.86 PGR (0.53) ATMGAAPGRALDH1A1LMNA
SCHEMBL965024 0.85 ALDH1A1 (0.55) GAAPGRALDH1A1LMNASLC1A3
SCHEMBL965914 0.80 CES1 (0.61) GAAPGRALDH1A1LMNAIDH1
SCHEMBL27741918 0.79 MEN1 (0.56) PGRALDH1A1LMNAMEN1KMT2A
SCHEMBL967450 0.79 MEN1 (0.56) PGRALDH1A1LMNAMEN1KMT2A
SCHEMBL964905 0.76 LMNA (0.55) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL27741919 0.76 LMNA (0.55) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL8643785 0.76 CA12 (0.57) GAAALDH1A1LMNAMEN1KMT2A
SCHEMBL25167208 0.75 EPHX1 (0.47) GAAPGRALDH1A1LMNAMEN1
SCHEMBL966639 0.75 EPHX1 (0.47) GAAPGRALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2024329-B1 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE SPA (IT) 2013-07-31 EP claimed
US-7868046-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them DOMPE' PHA.R.MA S.P.A. (IT) 2011-01-11 US claimed
US-20100152256-A1 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them DOMPE' PHA.R.MA S.P.A. (IT) 2010-06-17 US claimed
US-7652169-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them Dompe' Pha. R. Ma S.p.A. (IT) 2010-01-26 US claimed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US claimed
EP-2024329-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' pha.r.ma s.p.a. (IT) 2009-02-18 EP claimed
WO-2007135080-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA. S.P.A. (IT) 2007-11-29 WO claimed
US-11932683-B2 Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets NEW YORK UNIVERSITY (US) 2024-03-19 US disclosed
US-20230151081-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS UNIV NEW YORK (US) 2023-05-18 US disclosed
US-11453715-B2 Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets NEW YORK UNIVERSITY (US) 2022-09-27 US disclosed
EP-3848046-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E New York University (US) 2021-07-14 EP disclosed
US-20210009664-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS UNIV NEW YORK (US) 2021-01-14 US disclosed
EP-3441474-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E UNIV NEW YORK (US) 2020-07-22 EP disclosed
US-7652169-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them Dompe' Pha. R. Ma S.p.A. (IT) 2010-01-26 US disclosed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed
EP-2024329-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' pha.r.ma s.p.a. (IT) 2009-02-18 EP disclosed
WO-2007135080-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA. S.P.A. (IT) 2007-11-29 WO disclosed
WO-2007135080-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA. S.P.A. (IT) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11453715-B2 Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets CXCR1, CXCR2, CXCR5 ATM 4465/4885GAA 3866/4885PGR 4137/4885
US-20100152256-A1 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them CCR2, CXCR2, CXCR4 ATM 4716/4885GAA 4303/4885PGR 401/4885
US-20230151081-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS CXCR1, CXCR2, CXCR5 ATM 4465/4885GAA 3866/4885PGR 4137/4885
US-11932683-B2 Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets CXCR1, CXCR2, CXCR5 ATM 4465/4885GAA 3866/4885PGR 4137/4885
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them CCR2, CXCR2, CXCR3 ATM 4577/4885GAA 4128/4885PGR 366/4885
US-20210009664-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS CXCR1, CXCR2, CXCR5 ATM 4465/4885GAA 3866/4885PGR 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.